SG Americas Securities LLC Acquires Shares of 6,187 ICU Medical, Inc. (NASDAQ:ICUI)

SG Americas Securities LLC acquired a new stake in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,187 shares of the medical instruments supplier's stock, valued at approximately $859,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Harvest Fund Management Co. Ltd bought a new position in ICU Medical during the fourth quarter valued at approximately $33,000. Quarry LP raised its position in ICU Medical by 764.3% in the fourth quarter. Quarry LP now owns 242 shares of the medical instruments supplier's stock worth $38,000 after acquiring an additional 214 shares during the period. Murphy & Mullick Capital Management Corp bought a new position in ICU Medical in the fourth quarter worth approximately $52,000. Venturi Wealth Management LLC raised its position in ICU Medical by 64.0% in the fourth quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier's stock worth $82,000 after acquiring an additional 206 shares during the period. Finally, Russell Investments Group Ltd. raised its position in ICU Medical by 88.8% in the fourth quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier's stock worth $99,000 after acquiring an additional 300 shares during the period. Institutional investors own 96.10% of the company's stock.

Insider Transactions at ICU Medical

In related news, Director Elisha W. Finney sold 600 shares of the firm's stock in a transaction on Monday, May 19th. The shares were sold at an average price of $138.92, for a total transaction of $83,352.00. Following the completion of the transaction, the director now directly owns 3,252 shares of the company's stock, valued at approximately $451,767.84. This trade represents a 15.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David C. Greenberg sold 1,942 shares of the firm's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $143.66, for a total transaction of $278,987.72. Following the transaction, the director now directly owns 6,760 shares of the company's stock, valued at $971,141.60. The trade was a 22.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 36,097 shares of company stock valued at $4,860,156 over the last three months. Corporate insiders own 1.50% of the company's stock.

ICU Medical Price Performance

Shares of NASDAQ ICUI traded down $0.84 during midday trading on Friday, reaching $127.74. The stock had a trading volume of 248,995 shares, compared to its average volume of 274,282. The stock has a 50-day moving average of $134.95 and a 200-day moving average of $147.62. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.52 and a current ratio of 2.59. The company has a market capitalization of $3.14 billion, a price-to-earnings ratio of -33.35 and a beta of 0.88. ICU Medical, Inc. has a 12-month low of $111.97 and a 12-month high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.23 by $0.49. The firm had revenue of $599.49 million during the quarter, compared to analysts' expectations of $574.15 million. ICU Medical had a negative net margin of 3.87% and a positive return on equity of 6.75%. The company's revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.96 earnings per share. As a group, research analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Wall Street Zen upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a research report on Sunday, May 18th. Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a research report on Tuesday, April 8th. Raymond James Financial decreased their price target on shares of ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating on the stock in a research report on Friday, May 9th. Finally, KeyCorp decreased their price target on shares of ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a research report on Monday, April 21st. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $192.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.